Is the clinical profile of women treated with tibolone similar to that of women receiving a classical estrogen-progestogen therapy? Data from a nationwide survey in France;Le profil clinique des femmes qui utilisent la tibolone est-il le même que celui des femmes utilisant un traitement hormonal classique? Données d'une enquête nationale en France

Gynecologie Obstetrique et Fertilite

Volumn 34, Issue 3, 2006, Pages 224-232

  Jamin, C ^a   Bourg, F ^b   Legeai, J ^c   Senoussi, S ^d  

^a BICHAT HOSPITAL   (France)

^b SOFRES Medical   (France)

^c Rédasciences santé   (France)

^d Organon   (France)

Author keywords

Breast cancer; Endometrial cancer; Epidemiology; Hormone replacement therapy; Observational studies; Risk factors; Tibolone

Indexed keywords

ESTROGEN; GESTAGEN; TIBOLONE;

ADULT; AGED; ANAMNESIS; ARTICLE; BREAST CANCER; BREAST DISEASE; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FRANCE; GYNECOLOGY; HEALTH SURVEY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTALGIA; MENOPAUSE; PATIENT SELECTION; UTERUS; UTERUS BLEEDING;

EID: 33645373030     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2006.01.027     Document Type: Article

References (41)

1. A. Gompel, M. Chaouat, D. Jacob, J.Y. Perrot, H.J. Kloosterboer, and W. Rostene In vitro studies of tibolone in breast cells Fertil. Steril. 78 2002 351 359
2. A.R. Genazzani, L.J. Benedek-Jaszmann, D.M. Hart, L. Andolsek, P.M. Kicovic, and L. Tax Org OD 14 and the endometrium Maturitas 13 1991 243 251
3. D. Botsis, D. Kassanos, D. Kalogirou, G. Antoniou, N. Vitoratos, and P. Karakitsos Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low-dose estrogen or tibolone treatment: a comparison Maturitas 26 1997 57 62
4. M. Dören, A. Rubig, H.J. Coelingh Bennink, and W. Holzgreve Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy Menopause 6 1999 299 306
5. C. Egarter, J. Huber, R. Leikermoser, R. Haidbauer, H. Pusch, and F. Fischl Tibolone vs conjugated estrogens and sequential progestogen in the treatment of climacteric complaints Maturitas 23 1996 55 62
6. W. Hänggi, N. Bersinger, H.J. Altermatt, and M.H. Birkhauser Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users Maturitas 27 1997 133 143
7. M. Hammar, S. Christau, J. Nathorst-Boos, T. Rud, and K. Garre A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms Br. J. Obstet. Gynaecol. 105 1998 904 911
8. E.P. Morris, P.O. Wilson, J. Robinson, and J.M. Rymer Long-term effects of tibolone on the genital tract in postmenopausal women Br. J. Obstet. Gynaecol. 106 1999 954 959
9. N. Colacurci, D. Mele, P. De Franciscis, V. Costa, N. Fortunato, and L. De Seta Effects of tibolone on the breast Eur. J. Obstet. Gynecol. Reprod. Biol. 80 1998 235 238
10. C.T. Erel, K. Elter, C. Akman, G. Ersavasti, A. Altug, and H. Seyisoglu Mammographic changes in women receiving tibolone therapy Fertil. Steril. 69 1998 870 875
11. F. Sendag, M. Cosan Terek, S. Ozsener, K. Oztekin, O. Bilgin, and I. Bilgen Mammographic density changes during different postmenopausal hormone replacement therapies Fertil. Steril. 76 2001 445 450
12. T. Kutlu, C. Ficicioglu, T. Basaran, E. Basaran, and T. Topaloglu Mammographic breast density changes after 1:year of tibolone use Maturitas 48 2004 133 136
13. I. Valdivia, I. Campodonico, A. Tapia, M. Capetillo, A. Espinoza, and P. Lavin Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women Fertil. Steril. 81 2004 617 623
14. G. Emons, G. Fleckenstein, B. Hinney, A. Huschmand, and W. Heyl Hormonal interactions in endometrial cancer Endocr. Relat. Cancer 7 2000 227 242
15. M.E. Sherman Theories of endometrial carcinogenesis: a multidisciplinary approach Mod. Pathol. 13 2000 295 308
16. R.G. Dumitrescu, and I. Cotarla Understanding breast cancer risk-where do we stand in 2005? J. Cell. Mol. Med. 9 2005 208 221
17. J.A. Cauley, J.P. Gutai, L.H. Kuller, J. Scott, and M.C. Nevitt Black-white differences in serum sex hormones and bone mineral density Am. J. Epidemiol. 139 1994 1035 1046
18. V. Beral the Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 2003 419 427
19. V. Beral, D. Bull, G. Reeves the Million Women Study Collaborators Endometrial cancer and hormone-replacement therapy in the Million Women Study Lancet 365 2005 1543 1551
20. P. Ardilly Les techniques des sondages 1994 Éditions Technip Paris
21. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, and M.L. Stefanick Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
22. M. Espí Risques du THS:: doutes et certitudes Lettre Gynecol. 295 suppl 2004 1 4
23. C.S. de Vries, S.E. Bromley, H. Thomas, and R.D. Farmer Tibolone and endometrial cancer: a cohort and nested case-control study in the UK Drug Saf. 28 2005 241 249
24. C. Byrne, C. Schairer, J. Wolfe, N. Parekh, M. Salane, and L.A. Brinton Mammographic features and breast cancer risk: effects with time, age, and menopause status J. Natl. Cancer Inst. 87 1995 1622 1629
25. N.F. Boyd, J.W. Byng, R.A. Jong, E.K. Fishell, L.E. Little, and A.B. Miller Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study J. Natl. Cancer Inst. 87 1995 670 675
26. B. Karlsson, S. Granberg, M. Wikland, P. Ylostalo, K. Torvid, and K. Marsal Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding-a Nordic multicenter study Am. J. Obstet. Gynecol. 172 1995 1488 1494
27. L.P. O'Connell, M.H. Fries, E. Zeringue, and W. Brehm Triage of abnormal postmenopausal bleeding: a comparison of endometrial biopsy and transvaginal sonohysterography vs fractional curettage with hysteroscopy Am. J. Obstet. Gynecol. 178 1998 956 961
28. L. Elit Endometrial cancer. Prevention, detection, management, and follow-up Can. Fam. Physician 46 2000 887 892
29. G. Robertson Screening for endometrial cancer Med. J. Aust. 178 2003 657 659
30. D.S. Buist, A.Z. LaCroix, W.E. Barlow, E. White, J.A. Cauley, and D.C. Bauer Bone mineral density and endogenous hormones and risk of breast cancer in postmenopausal women Cancer Causes Control 12 2001 213 222
31. A. McTiernan, K.B. Rajan, S.S. Tworoger, M. Irwin, L. Bernstein, and R. Baumgartner Adiposity and sex hormones in postmenopausal breast cancer survivors J. Clin. Oncol. 21 2003 1961 1966
32. L. Bernstein Epidemiology of endocrine-related risk factors for breast cancer J. Mammary Gland Biol. Neoplasia 7 2002 3 15
33. P.J. Goodwin, G. de Boer, R.M. Clark, P. Catton, and S. Redwood Cyclical mastopathy and premenopausal breast cancer risk Breast Canc Treat 33 1994 63 73
34. G. Plu-Bureau, J.C. Thalabard, R. Sitruck-Ware, B. Asselain, and P. Mauvais-Jarvis Cyclical mastalgia as a marker of breast cancer susceptibility: result of a case-control study among French women Brit J Canc 65 1992 945 949
35. M.M.J. MacNicholas, J.P. Heneghan, M.H. Milner, T. Tunney, J.B. Hourihane, and D.P. Mac Erlaine Pain and increased mammographic density in women receiving hormone replacement therapy Am R Roentgenol 163 1994 311 315
36. L.C. Hartmann, T.A. Sellers, M.H. Frost, W.L. Lingle, and A.C. Degrim Benign breast disease and the risk of breast cancer N. Engl. J. Med. 353 2005 229 237
37. P. Kenemans, L. Speroff the International Tibolone Consensus Group Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group Maturitas 51 2005 21 28
38. E.J. Wierik, P.T. Hendricks, and M. Boerstoel-Streefland Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies: a UK MediPlus study Climacteric 7 2004 197 209
39. N.F. Col, and S.G. Pauker The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience? Ann. Intern. Med. 139 2003 923 929
40. S. Shapiro Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial Climacteric 6 2003 302 313
41. S. Shapiro Effets du THS sur le risque de cancer du sein et de maladie cardiovasculaire:: validit́ de l'́vidence ́pid́ miologique Gynecol. Obstet. Fertil. 32 2004 382 390